Custom Search

News

Tuesday 12 March 1996

Pefloxacin penetration into human necrotic pancreatic tissue.

By: E. Bertazzoni Minellia, A. Beninia, A. Munera

Antibiotic prophylaxis may be useful in acute necrotising pancreatitis, a disease associated with a considerable incidence of infectious complications.

The aim of this study was to assess pefloxacin penetration into necrotic pancreatic tissue during human necrotic pancreatitis. Ten patients (mean age 532 174 years) with severe acute pancreatitis (mean Ranson score 43) were studied. Pefloxacin was administered at a dose of 400 mg bd every 12 h by iv infusion (bolus, 15 min). Intraoperative samples of necrotic pancreatic tissue and blood were collected simultaneously 1, 2, 45, 6, 85 or 10 h after the last pefloxacin administration in patients treated for 1, 3, 4, 7, 8, 17 or 20 days. Drug concentrations were determined by the microbiological agar-well diffusion method (Escherichio coli Kp 05124 as test micro-organism in Isosensitest Agar). Levels in serum ranged from 20 to 90 mg/L (at 2 and 6 h, respectively), in necrotic pancreatic tissue from 20 to 290 g/g depending on different sampling time. Maximum tissue peak concentrations appeared between 4 and 6 h. The necrotic pancreatic tissue/serum concentration ratio ranged from 0/9 to 5/1, values depending on tissue sample collection. Therapeutic conantrations (20.6g/g) above the MIC of potentially pathogenic enteric microorganisms were still present in necrotic pancreatic tissue 10 h after the last drug administration. Pefloxacin appeared to concentrate in necrotic pancreatic tissue, without appreciable accumulation after multiple-dose administration. The pefloxacin concentrations in necrotic pancreatic tissue showed high variability, depending on the degree of necrosis. inflammation and sample vascularization. Our results provided evidence of good, prompt penetration of pefloxacin into necrotic pancreatic tissue. Pefloxacin seems to exhibit favourable pharmacokinetic and pharmaccdynamic properties for pancreatic infections.

Use of this site is subject to the following terms of use